Certara Services Archives

Case Study

Using Real Word Evidence to Enhance Drug Development

Real-world evidence (RWE) has emerged as an increasingly important tool in the drug development process,1…

CertaraApril 5, 2023

Conference

RAPS Convergence 2025

– – Booth

CertaraMarch 20, 2023

Conference

Asembia AXS26 Summit

–

CertaraFebruary 15, 2023

Conference

DIA Annual Meeting 2026

CertaraFebruary 15, 2023

Conference

ISPOR International Annual Conference 2026

–

CertaraFebruary 15, 2023

Conference

ACCP Annual Meeting

– – Booth

CertaraJuly 15, 2022

Case Study

Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another

Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare genetic disease that causes abnormal blood clot…

CertaraJune 1, 2022

Conference

ASCPT 2026 Annual Meeting

CertaraMarch 7, 2022

Blog

Choosing an eCTD Submissions Vendor: Your Complete Checklist

September 3, 2025 Selecting the right electronic submission vendor for regulatory submissions to health authorities…

CertaraJanuary 28, 2022

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

CertaraDecember 15, 2021

Certara Services

Using Real Word Evidence to Enhance Drug Development

RAPS Convergence 2025

Asembia AXS26 Summit

DIA Annual Meeting 2026

ISPOR International Annual Conference 2026

ACCP Annual Meeting

Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another

ASCPT 2026 Annual Meeting

Choosing an eCTD Submissions Vendor: Your Complete Checklist

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

Newsletter sign up

Quick links

Solutions

Contact